• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

    11/23/22 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company.

    "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointments follow a robust search and build on the work we have done to refresh our Board, with five individuals joining over the last five years. We look forward to benefitting from Mark's and Dan's financial and operational expertise."

    "With a reinvigorated innovation engine and growth initiatives that continue to gain traction, we are excited to welcome two new directors to our Board whose expertise will support our strong and growing momentum," said Dr. Udit Batra, CEO and President, Waters Corporation. "Both Dan and Mark are experienced board members who have overseen highly dynamic companies and I am looking forward to collaborating with them. Dan brings two decades of finance leadership at Boston Scientific, where he oversaw successful margin and revenue growth initiatives. Mark brings deep operational expertise having led global sciences companies through transformations and significant periods of growth."

    "I am honored to join the Board of Waters, which has a strong reputation for innovation and leadership in life sciences," said Mr. Brennan.

    "Waters has undertaken a comprehensive and impressive transformation to position the Company for growth, and I am excited to contribute to the Board at this important time," said Mr. Vergnano.

    The addition of Mr. Brennan and Mr. Vergnano is part of the Board's ongoing refreshment process. With these appointments, the Board will expand to nine members, eight of whom are independent and five of whom have been appointed in the last five years.

    In his current role as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, Mr. Brennan is responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development. Prior to that, he was the company's Senior Vice President and Corporate Controller and held other roles of increasing responsibility within finance. He holds a B.S. in Finance and Investments and an M.B.A from Babson College and is also a certified public accountant.

    Mr. Vergnano currently serves as a Partner at Sea Shell Partners. He previously served as the Chairman, President and Chief Executive Officer of The Chemours Company. Prior to that, he held roles of increasing responsibility at E.I. Dupont De Nemours & Company, culminating in his role as Executive Vice President. Mr. Vergnano received a B.S. from the University of Connecticut and an M.B.A. from Virginia Commonwealth University. He currently serves on the Board of Johnson Controls International.

    Additional Resources

    • See list of the Waters Board of Directors
    • Connect with Waters via Twitter, Facebook and LinkedIn

    About Waters Corporation (www.waters.com)

    Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

    Waters is a trademark of Waters Corporation.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005848/en/

    Get the next $WAT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    SEC Filings

    See more
    • SEC Form 425 filed by Waters Corporation

      425 - WATERS CORP /DE/ (0001000697) (Subject)

      7/14/25 5:25:11 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Waters Corporation

      425 - WATERS CORP /DE/ (0001000697) (Subject)

      7/14/25 5:23:10 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Waters Corporation

      425 - WATERS CORP /DE/ (0001000697) (Subject)

      7/14/25 5:18:16 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

      Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five  Delivers a

      7/14/25 6:15:00 AM ET
      $BDX
      $WAT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call

      MILFORD, Mass., July 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2025 financial results conference call on Monday, August 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 2nd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of

      7/11/25 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

      News Summary Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security.Integration of Alliance™ iS HPLC System with Empower™ Software ensures user actions are identifiable and auditable.Minimizes common user errors by up to 40% and enhances audit readiness by providing end-to-end traceability and data integrity.BRUGES, Belgium and MILFORD, Mass., June 17, 2025 /PRNewswire/ -- 54th International Symposium on High-Performance Liquid Phase Separations and Related Techniques - Waters Corporation (NYSE:WAT) today announced the release of the Alliance iS HPLC System Software version 2.0, a significant advancement that delivers c

      6/17/25 10:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

      MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

      5/21/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Heather Knight to Board of Directors

      MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

      8/14/24 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Richard Fearon to Board of Directors

      Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

      3/28/23 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Financials

    Live finance-specific insights

    See more
    • Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

      Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five  Delivers a

      7/14/25 6:15:00 AM ET
      $BDX
      $WAT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call

      MILFORD, Mass., July 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2025 financial results conference call on Monday, August 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least September 2nd, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of

      7/11/25 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Waters Corporation

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      11/12/24 11:54:03 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/14/24 9:37:22 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/13/24 5:17:31 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Knight Heather was granted 68 shares, increasing direct ownership by 11% to 681 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      7/1/25 7:20:58 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 68 shares, increasing direct ownership by 3% to 2,479 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      7/1/25 7:18:41 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP, Waters Division Carpio Robert L Iii covered exercise/tax liability with 134 shares, decreasing direct ownership by 5% to 2,656 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      6/26/25 4:16:39 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials